FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Thymalin 10mg research peptide vial
Immune

Thymalin

Thymus peptide complex

A thymic peptide preparation studied in immune-regulation research.

$99

In stock · ships in 1–2 business days

  • ✓ 98.845% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
thymicimmune research

Research Summary

Thymalin is a thymus-derived peptide preparation studied in preclinical research for its role in T-cell regulation and immune-homeostasis models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Thymalin: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is thymalin?

Thymalin is a thymus-derived peptide preparation. Its developers described isolating natural thymic peptides from calf thymus by mild acid extraction and introducing a preparation of these peptides, named Thymalin, into practice. They also reported isolating one immunomodulatory component, the dipeptide Glu-Trp, by reversed-phase HPLC [1]. A 2023 paper from the same research network identified Lys-Glu (KE) and Glu-Trp (EW) dipeptides as active substances of thymalin [5].

Because thymalin is described as a complex rather than a single molecule, it has no single sequence, formula, or molecular weight to report. Some databases attach the name to unrelated thymic peptides. For example, PubChem lists "Thymalin" as a synonym on its record for nonathymulin, a nine-residue thymic peptide that is a different compound [7]. We do not use that record as an identity reference.

Thymalin is also different from thymosin alpha-1, a single defined 28-residue peptide. See our thymosin alpha-1 page for that compound.

Thymalin molecular identity
TypeThymic polypeptide complex (not a single defined sequence)
Origin in the literaturePeptides isolated from calf thymus by mild acid extraction
Components describedLys-Glu (KE) and Glu-Trp (EW) dipeptides, per its developers
PubChemNo verified record. The record listing "Thymalin" as a synonym (CID 3085284) is nonathymulin, a different peptide.

Who has studied it

The thymalin literature is concentrated in one research group. Most indexed papers come from Vladimir Morozov, Vladimir Khavinson, and colleagues at institutions in St. Petersburg, Russia, including the St. Petersburg Institute of Bioregulation and Gerontology [1] [3] [4] [5]. Much of the older literature was published in Russian-language journals [2] [3].

A smaller number of studies come from other groups in the region, such as a rat tumor-model study from Rostov-on-Don [6]. Independent replication outside this research community is scarce. Readers should weigh the findings below with that concentration in mind.

Published research

T-cell differentiation in early work

The developers' 1997 review reported that both the natural preparation and synthetic dipeptides derived from it influenced T-cell differentiation, intracellular cyclic nucleotides, and interleukin-2 and interferon release by blood lymphocytes in their experiments [1].

Hematopoietic stem cell differentiation

In a 2020 in vitro study, the group exposed human hematopoietic stem cells to thymalin and reported lower expression of the markers CD44 and CD117 and higher expression of CD28, which the authors interpreted as stimulation of differentiation toward mature CD28-positive T cells [4].

Cytokine release in a cell model

A 2023 study combined molecular docking and bioinformatic analysis of the KE and EW dipeptides with an in vitro model of LPS-induced inflammation in human peripheral blood mononuclear cells from four donors. The authors reported that thymalin and both dipeptides reduced IL-1beta, IL-6, and TNF-alpha in that model [5].

Tumor model

A 2018 study in rats with transplanted sarcoma 45 reported tumor growth suppression and microstructural changes in the thymus under the conditions the authors tested [6].

State of the human evidence

The developers have published clinical reports, largely in Russian-language journals, including a long-term observational study in older adults [3]. These reports come from the same research community, and we found no independent, registered randomized trials of thymalin in the indexed literature. We do not summarize their results here.

Findings from cell and animal models should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. We found no FDA-approved drug containing thymalin in Drugs@FDA (checked October 12, 2026) [8].
  • Compounding. Thymalin is not named on FDA's page of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) [9], nor on FDA's list of bulk drug substances nominated under section 503A (updated May 14, 2026) [10].

Rejuvatide supplies thymalin strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

The current lot of Rejuvatide thymalin was tested by an independent laboratory for purity by HPLC with mass-spectrometric identification, and has a separate USP <85> endotoxin certificate for the same lot. Both certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Browse related compounds in immune and cellular research peptides.

Storage of lyophilized material

Thymalin ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Thymalin.

98.845%HPLC purity
Lot 2025032801-1Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Thymalin FAQ

What is thymalin?

Thymalin is a thymus-derived peptide preparation, described by its developers as a complex of peptides isolated from calf thymus. The same group has identified the dipeptides Lys-Glu and Glu-Trp as active components.

Who has researched thymalin?

Most published research comes from one group in St. Petersburg, Russia (Morozov, Khavinson and colleagues), much of it in Russian-language journals. Independent replication is limited.

Is thymalin the same as thymosin alpha-1?

No. Thymosin alpha-1 is a single defined 28-residue peptide. Thymalin is described as a complex of thymic peptides.

Is thymalin FDA approved?

No. Thymalin is not an FDA-approved drug.

What size does Rejuvatide offer?

Thymalin is available as a 10mg vial of lyophilized powder.

Is thymalin for human use?

No. Rejuvatide sells thymalin for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. Morozov VG, Khavinson VK. Int J Immunopharmacol. 1997;19(9-10):501-5. PubMed 9637345
  2. Sofronov BN, Morozov VG, Khavinson VKh, et al. Fiziol Cheloveka. 1984;10(2):229-33. PubMed 6335878
  3. Khavinson VKh, Morozov VG. Adv Gerontol. 2002;10:74-84. PubMed 12577695
  4. Khavinson VK, Linkova NS, Kvetnoy IM, et al. Bull Exp Biol Med. 2020;170(1):118-122. PubMed 33237528
  5. Linkova N, Khavinson V, Diatlova A, et al. Int J Mol Sci. 2023;24(17). PubMed 37686182
  6. Zhukova GV, Schikhlyarova AI, Barteneva TA, et al. Bull Exp Biol Med. 2018;165(1):80-83. PubMed 29797130
  7. PubChem. Nonathymulin, Compound CID 3085284 (lists "Thymalin" among synonyms). National Library of Medicine. Source
  8. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs database (searched October 12, 2026). Source
  9. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  10. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act (updated May 14, 2026). Source